|
⚲
|
| Keyboard |
| HEP Management Corporation
✚
|
|
|---|---|
| CRD # | 161855 |
| SEC # | 801-78087 |
| CIK # | 0001618035 |
| AUM | 426.6 M (2026-03-31) |
| Employees | 9 (89% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-217-4515 |
| Address | 565 Fifth Avenue New York, NY 10017-2470 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation Limited partners pay HEP a management fee based on each limited partner’s committed capital, however, Fund II no longer pays management fees as of July 25, 2025. Generally, HEP charges an annual management fee of 2% of each limited partner’s committed capital, payable quarterly in advance on January 1st, April 1st, July 1st and October 1st of each calendar year. During the investment period, the annual management fee is based on the total capital commitments of such Fund’s limited partners. Thereafter, the management fee for most Funds is computed based on the limited partners’ funded commitments that remain invested in portfolio companies (excluding write- offs). Fund IV’s management fee is calculated based on each limited partner's pro rata share of the aggregate amount invested by Fund IV in all portfolio investments which have not been disposed of as of the end of the immediately preceding quarterly period. Fund II and Fund III are beyond their investment periods. Fund IV’s investment period will end on the earlier of five years from the final closing, the date on which all unfunded commitments have been reduced to $0, the date of the first investment by a successor fund, the dissolution of the Fund or such date as determined by the General Partner in its discretion. HEP, the GPs and/or its affiliates may perform management, advisory, transaction-related, financial advisory and other services for, and may (although generally they do not) receive fees from portfolio companies of the Funds, including transaction fees, break-up fees, monitoring fees and other similar fees. These fees may be substantial and may be paid in cash, in securities of portfolio companies or otherwise and are in addition to the management fees set forth above. All break-up fees paid to HEP or its affiliates in connection with a Fund’s unconsummated transactions will first be applied to offset broken deal expenses of HEP and/or its affiliates and the Fund’s allocable share of the balance will be credited against management fees. In addition, each Fund’s allocable share of any transaction, closing, consulting, monitoring or other fees paid to HEP, the GPs or its affiliates by a portfolio company will be fully credited against management fees incurred by limited partners. In addition, limited partners in Funds II, III and IV are responsible for all expenses related to its operations (other than normal operating expenses of HEP incidental to the provision of the day-to- day administrative services to the Funds, which will be borne by HEP), including fees, costs and expenses directly related to the purchase and sale of securities, taxes, fees and expenses of auditors, third party accounting and administrative service providers and counsel, expenses of HEP’s board of advisors and annual meetings, insurance, litigation expenses and any extraordinary expenses. Fund II, III and IV shall each bear its respective organizational expenses incurred in the formation of such Fund and the offering of the interests thereunder up to a maximum amount as specified in each Fund’s governing documents. Organizational expenses in excess of the respective caps and any placement agent fees paid by the applicable HEP Fund will be 100% offset against any management fees incurred for such Fund. Similarly, a portfolio company of a Fund may reimburse HEP for expenses (including, without limitation, travel expenses) incurred by HEP in connection with its performance of services for such portfolio company. Managing Members, Special Members, Venture Members and other employees of HEP may receive a portion of the management fees, carried interest or other compensation received by HEP or the GPs. The precise amount of, and the manner and calculation of, the management fees for each Fund are set forth in the respective Fund’s governing documents and/or other documentation received by each investor prior to investment in such Fund. The amount of management fees, fund expenses, transaction fees and any offset thereof may differ from one Fund to another, as well as among investors in the same Fund. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7 – Types of Clients HEP provides portfolio management services to its clients, which are private funds. Investment advice is provided directly to the Funds and not individually to investors in such Fund. The Funds limit their respective investors to persons who are “accredited investors” as defined in the Securities Act of 1933 and “qualified clients” and/or “qualified purchasers” as defined in the Investment Company Act of 1940, as amended. Although the minimum contribution for a limited partner in each Fund is at a set amount, commitments less than these minimums were and may be accepted at the sole discretion of each Fund’s GP. Fund II, Fund III and Fund IV are closed. More information about the HEP Funds is available in each Fund’s respective offering documents. Investors in HEP’s Funds include a broad range of U.S. and non-U.S. investors, including, among others, high net worth individuals or their investment advisors, corporate pension plans, private funds, corporations, hospital systems, and health insurance companies. In addition, employees and other persons associated with HEP and/or its affiliates may make capital contributions to the Funds. Co- investment opportunities may be given to limited partners when additional capital is necessary for a Fund investment. The Managers of the Funds’ GP are contractually committed to co-invest in each Fund investment as described in each Fund’s Limited Partnership Agreement. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Health Enterprise Partners IV LP | [2022-03-25] | 236.3 M | |
| Offered $250,000,000 · Filed 2021-12-02 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $250,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Health Enterprise Partners III LP | [2018-03-28] | 177.5 M | 153.3 M |
| Offered $177,500,000 · Filed 2018-07-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Health Enterprise Partners II LP | [2012-10-09] | 136.4 M | 37.0 M |
| Offered $136,400,000 · Filed 2014-07-08 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Health Enterprise Partners LP | 2012-02-27 | 1.1 M | |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 426.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 426.6 |
| By Discretionary | ||
| Discretionary | 3 | 426.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 426.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 426.6 | |
| Total | 3 | 426.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Robert Schulz | Executive Officer | 15 | 3 | |
| Daniel Cain | Executive Officer | 5 | 3 | |
| David Tamburri | Executive Officer | 38 | 2 | |
| Ezra Mehlman | Executive Officer | 11 | 2 | |
| Richard Stowe | Executive Officer | 11 | 2 | |
| Peter Tedesco | Executive Officer | 3 | 2 | |
| Hep Associates IV LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001618035] | |
| 4 | [0001618035] | |
| SC 13D | [0001618035] | |
| SC 13G | [0001618035] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| HEP Investments LLC | ZIVO Bioscience Inc | [2018-04-25] |
| HEP Investments LLC | ZIVO Bioscience Inc | [2015-05-01] |
| HEP Investments LLC | Health Enhancement Products Inc | [2014-09-04] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| HEP Investments LLC | |
| Health Enhancement Products Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Health Enhancement Products Inc ZIVO
Common Stock
|
2016-04-29 | Buy | 107,064 | $0.08 | 8,565 |
|
Health Enhancement Products Inc ZIVO
Accrued Interest converting into Common Stock · derivative
|
2016-04-15 | Buy | 5,902,729 | ||
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2016-03-01 | Buy | 2,500,000 | $250,000.00 | 625,000,000,000 |
|
Health Enhancement Products Inc ZIVO
Common Stock Purchase Warrant · derivative
|
2016-03-01 | Buy | 250,000 | ||
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2016-01-27 | Buy | 2,500,000 | $250,000.00 | 625,000,000,000 |
|
Health Enhancement Products Inc ZIVO
Common Stock Purchase Warrant · derivative
|
2016-01-27 | Buy | 250,000 | ||
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2015-10-29 | Buy | 2,500,000 | $250,000.00 | 625,000,000,000 |
|
Health Enhancement Products Inc ZIVO
Common Stock Purchase Warrant · derivative
|
2015-10-29 | Buy | 250,000 | ||
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2015-10-08 | Buy | 2,500,000 | $250,000.00 | 625,000,000,000 |
|
Health Enhancement Products Inc ZIVO
Common Stock Purchase Warrant · derivative
|
2015-10-08 | Buy | 250,000 | ||
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2015-09-24 | Disposed to issuer | 250,000 | $30,000.00 | 7,500,000,000 |
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2015-09-02 | Buy | 2,500,000 | $250,000.00 | 625,000,000,000 |
|
Health Enhancement Products Inc ZIVO
Common Stock Purchase Warrant · derivative
|
2015-09-02 | Buy | 250,000 | ||
|
Health Enhancement Products Inc ZIVO
Common Stock Purchase Warrant · derivative
|
2015-07-07 | Buy | 250,000 | ||
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2015-07-07 | Buy | 2,500,000 | $250,000.00 | 625,000,000,000 |
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2015-06-26 | Buy | 2,500,000 | $250,000.00 | 625,000,000,000 |
|
Health Enhancement Products Inc ZIVO
Common Stock Purchase Warrant · derivative
|
2015-06-26 | Buy | 250,000 | ||
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2015-06-05 | Disposed to issuer | 250,000 | $30,000.00 | 7,500,000,000 |
|
Health Enhancement Products Inc ZIVO
Convertible Debt · derivative
|
2015-05-01 | Buy | 2,372,200 | $237,200.00 | 562,685,840,000 |
|
Health Enhancement Products Inc ZIVO
Common Stock Purchase Warrant · derivative
|
2015-05-01 | Buy | 237,200 | ||
| showing 20 of 34 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Faction Ventures LLC
✚
|
CA | 432.6 M |
|
Cotulla Holdings LLC
✚
|
432.5 M | |
|
Republic Capital Adviser LLC
✚
|
NY | 430.9 M |
|
CRUX Capital Ltd
✚
|
TX | 427.6 M |
|
Care Equity Capital Management LP
✚
|
426.9 M | |
|
Blue Like an Orange Capital US LLC
✚
|
DC | 426.5 M |
|
Dubin Clark & Company Inc
✚
|
FL | 425.2 M |
|
Forward Consumer Partners LLC
✚
|
CT | 425.0 M |
|
Spring Lane Management LLC
✚
|
MA | 424.7 M |
|
Zarvona Energy LLC
✚
|
TX | 423.1 M |